Recent advances offer renewed opportunities to develop gene therapies for genetic disorders of surfactant dysfunction resulting from pathogenic variants in SFTPB, SFTPC, and ABCA3. There is no “one size fits all” approach for developing gene therapy vectors for SP-B, SP-C, and ABCA3 deficiencies. Here, ABCA3 is linked to hereditary disease.